Business Wire

Publication of Clinical Data Demonstrating Low Immunogenicity and Excellent Efficacy of Nuwiq® in Previously Untreated Patients

Del

Octapharma is delighted to announce the publication of interim data from the NuProtect study (GENA-05, NCT01712438), the first clinical data on treatment with Nuwiq® in previously untreated patients (PUPs), on August 16th 2017 as an Early View article in the internationally renowned medical journal Haemophilia.

The NuProtect study was initiated in March 2013 to investigate the immunogenicity, efficacy and safety of Nuwiq® in PUPs with severe haemophilia A, who are at the greatest risk of developing inhibitors. The ongoing study has enrolled 110 PUPs of any age or ethnicity who will receive Nuwiq® for up to 100 exposure days (EDs), making it one of the largest studies with a single FVIII product. Patients who previously received any FVIII concentrates or blood products containing FVIII are excluded from the study.

The recently published article describes interim results for 66 PUPs treated for at least 20 EDs, the time by which most inhibitors arise. The cumulative incidence (95% confidence interval) was 20.8% (10.7–31.0) for all inhibitors and 12.8% (4.5–21.2) for high-titre inhibitors. The study reported excellent efficacy of Nuwiq® in the prevention of bleeds, with median annual bleeding rates of 0 for spontaneous bleeds and 2.40 for all bleeds. Nuwiq® was also efficacious for the treatment of bleeds (92.4% of bleeds were controlled with one or two infusions) and as surgical prophylaxis (rated as “excellent” or “good” for 89% of surgical procedures). These interim results confirm the excellent haemostatic efficacy reported with Nuwiq® in previously treated patients.

Larisa Belyanskaya, Head of IBU Haematology, said: “We are very excited by the results of the NuProtect study and pleased that these interim data are now available as a publication in the specialist peer-reviewed journal Haemophilia. This is the first study to report data from PUPs treated with a rFVIII produced in a human cell line, and the results further differentiate Nuwiq ® from other products on the market.”

Olaf Walter, Board Member at Octapharma, added that “These data demonstrate low immunogenicity of Nuwiq ® in PUPs, the patient group at the greatest risk of inhibitor development, and confirm the excellent efficacy observed in previously treated patients. This publication is a further important step towards Octapharma’s goal of enabling patients with coagulation disorders to live a normal life.”

Octapharma would like to thank everyone involved in the study, in particular the patients and their families, without whom this research would not be possible.

About the NuProtect (GENA-05) study

The NuProtect clinical study (NCT01712438) is a phase 3, open-label, interventional clinical study being conducted across 38 centres, to evaluate at least 100 previously untreated patients (PUPs) with severe haemophilia A of all ages and ethnicities enrolled for study up to 100 exposure days (EDs) or 5 years maximum. Patients treated previously with any FVIII concentrates/blood products containing FVIII are excluded. The primary objective is to assess the immunogenicity of Nuwiq® by determining inhibitor activity using the Nijmegen-modified Bethesda assay at a central laboratory. Final data from the NuProtect study are expected to become available in 2019. More information on this trial is available at www.clinicaltrials.gov. An extension study (GENA-15, NCT01992549) will further evaluate the long-term immunogenicity, efficacy and safety of Nuwiq® in PUPs.

About Nuwiq ®

Nuwiq® is a 4th generation rFVIII protein1, produced in a human cell line without chemical modification or fusion with any other protein2. Nuwiq® is cultured without additives of human or animal origin2, is devoid of antigenic non-human protein epitopes3 and has a mean half-life of 17.1 hours4,5 and a high affinity for the von Willebrand coagulation factor6. Nuwiq® treatment has been assessed in seven completed clinical trials which included 201 PTPs7,8 (190 individuals) with severe haemophilia A, including 59 children9. Nuwiq® is approved for use in the treatment and prophylaxis of bleeding across all age groups of PTPs with haemophilia A in the EU, US, Canada, Australia, Latin America and Russia. Further worldwide submissions for Nuwiq® are planned.

References:
1. FDA Nuwiq® memorandum (STN 125555\0), 9 October 2014.
2. Casademunt E, et al. Eur J Haematol 2012; 89: 165-76.
3. Kannicht C, et al. Thromb Res. 2013;131:78-88.
4. Nuwiq® European Public Assessment Report, 22 May 2014.
5. NUWIQ® US Prescribing Information, September 2015.
6. Sandberg H, et al. Thromb Res 2012; 130: 808-17.
7. Valentino LA, et al. Haemophilia 2014; 20(Suppl. 1): 1-9
8. Lissitchkov T, et al. Haemophilia 2017; e-pub ahead of print; doi: 10.1111/hae.13251
9. Klukowska A, et al. Haemophilia 2016; 22, 232-39.

About Haemophilia A

Haemophilia A is an X-linked hereditary disorder caused by FVIII deficiency which, if left untreated, leads to haemorrhages in muscles and joints and consequently to arthropathy and severe morbidity. FVIII replacement prophylactic treatment reduces the number of bleeding episodes and the risk of permanent joint damage. This disorder affects one in every 5,000 to 10,000 men worldwide. Globally, 75% of haemophilia cases are left undiagnosed or untreated. The development of neutralising FVIII antibodies (FVIII inhibitors) against infused FVIII represents the most serious treatment complication. The cumulative risk of FVIII inhibitor development is reported to be currently up to 39%.

About Octapharma

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines. As a family-owned company, Octapharma believes in investing to make a difference in people’s lives and has been doing so since 1983; because it’s in our blood.

In 2016, the Group achieved €1.6 billion in revenue, an operating income of €383 million and invested €249 million to ensure future prosperity. Octapharma employs more than 7,100 people worldwide to support the treatment of patients in 113 countries with products across three therapeutic areas:

  • Haematology (coagulation disorders)
  • Immunotherapy (immune disorders)
  • Critical care

Octapharma owns six state-of-the-art production facilities in Austria, France, Germany, Mexico and Sweden.

For more information visit www.octapharma.com

Contact information

Octapharma AG
International Business Unit - Haematology
Olaf Walter
Olaf.Walter@octapharma.com
or
Larisa Belyanskaya
Larisa.Belyanskaya@octapharma.com
Tel: +41 55 4512121

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Rimilia Wins Expedia® Partner Solutions Account21.2.2019 11:00:00Pressemelding

Rimilia, a financial technology company, today announced that Expedia Partner Solutions (EPS), Expedia’s Business-to-Business partner network, selected Rimilia solutions to automate incoming payments. Rimilia will enable EPS to automate the application of their payments in 20 different currencies to open lodging supply/invoices from all of Expedia Group’s hotel, airline, car rental and holiday travel agency partners. Headquartered in Bellevue, Washington, Expedia Group is one of the world’s largest online travel companies with nearly $100 billion in gross bookings, $11 billion in revenue and 24,000 employees worldwide1. The Expedia Partner Solutions division supports thousands of travel partners with technology, travel supply and support services. Jeremy Hayes, Senior Manager for EAC Accounting at Expedia Partner Solutions, stated, “Our team manages cash and collection and applies payments from our travel partners all over the globe in multiple currencies. We have been looking for ways

emporia Showcases Four Products at Mobile World Congress21.2.2019 10:00:00Pressemelding

According to a 2018 emporia survey, 31 per cent of people over 65 and 50 per cent of 65 to 70-year-olds own a mobile phone with internet access. Meanwhile 85 per cent of smartphone users over the age of 65 use WhatsApp or other messenger services to stay in touch with friends and family. 59 per cent of grandchildren use WhatsApp to share their lives with grandparents. emporiaTOUCHsmart TOUCHsmart is a new clamshell smartphone from emporia. The combination of touch screen and physical keyboard is tailored to the needs of older generations. WhatsApp is pre-installed with a shortcut button, while emporia’s famous emergency system – which automatically calls up to five numbers at the touch of a button - instis a sense of security. emporiaSmart.3 The new Smart.3 smartphone has clear menu navigation in a stylish design. It features a 13 megapixel rear and 8 megapixel front camera and has a physical home button to make it simple to return to the main menu. The smartphone is splash proof and i

Toshiba Memory Corporation Develops New Bridge Chip Using PAM 4 to Boost SSD Speed and Capacity21.2.2019 09:52:00Pressemelding

Toshiba Memory Corporation, the world leader in memory solutions, today announced the development of a bridge chip that realizes high-speed and large-capacity SSDs. Using developed bridge chips with a small occupied area and low-power consumption, the company has succeeded in connecting more flash memory chips with fewer high-speed signal lines than with the conventional method of no bridge chips. This result was announced in San Francisco on February 20, at the International Solid-State Circuits Conference 2019 (ISSCC 2019). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190221005378/en/ Fig. 1 Connection using bridge chips (Graphic: Business Wire) In SSDs, multiple flash memory chips are connected to a controller that manages their operation. As more flash memory chips are connected to a controller interface, operating speed degrades, so there are limits to the number of chips that can be connected. In order to increase ca

GSMA: Low Power Mobile IoT Networks Now Available from All Leading IoT Operators Worldwide21.2.2019 09:00:00Pressemelding

The GSMA today announced that Mobile IoT or Low Power Wide Area (LPWA) networks are now globally available in licensed spectrum in 49 markets1 around the world following 93 launches by 50 different mobile operators across both LTE-M and NB-IoT. Coverage is now expected to reach approximately 93% of the world’s largest IoT markets by Q2 20192. According to GSMA Intelligence forecasts, by 2025 there will be 3.5 billion cellular IoT connections, including 1.9 billion licensed LPWA connections3. “The speed with which these networks have been standardized and deployed around the world is staggering. They are now available in every major IoT market encouraging the development of innovative new products and services across a wide range of sectors,” commented Alex Sinclair, Chief Technology Officer, GSMA. “The market clearly sees the benefit of solutions in licensed spectrum that offer flexibility, adaptability, security and lower cost. They are also future proofed for the 5G era and will supp

Meggitt Training Systems to Highlight Expanded Virtual and Live-Fire Solutions at IWA Outdoor Classics21.2.2019 09:00:00Pressemelding

With two European facilities to serve shooting range customers across the continent, Meggitt Training Systems will feature the latest virtual and live-fire products March 8-11, 2019, at IWA Outdoor Classics (stand #3-211) in Nuremberg, Germany. A leader for more than nine decades in the design, equipment and installation for law enforcement, defense and commercial ranges, Meggitt Training Systems has fielded more than 13,000 range systems worldwide, including over 75,000 live-fire target systems on 122 military bases. “Meggitt understands and serves Europe’s unique live-fire training requirements thanks in part to our regional facilities in Ashford and Waardenburg,” said Mark Mears, managing director for Meggitt Training Systems Ltd. “IWA Outdoor Classics attendees are welcome to see how our unrivalled expertise can facilitate the design and construction of new and upgraded shooting ranges.” Meggitt’s display of products at IWA will include: The XWT ProImage® projected target system re

New GSMA Report Highlights Global Role of Intelligent Connectivity21.2.2019 09:00:00Pressemelding

The GSMA today issued a new report, ‘Intelligent Connectivity: How the Combination of 5G, AI, Big Data and IoT Is Set to Change Everything ,’ highlighting how 5G networks, artificial intelligence (AI), smart platforms and the Internet of Things (IoT) is set to transform the lives of citizens and businesses around the world. The in-depth report draws on fresh interviews with senior representatives from Deutsche Telekom, GSMA Intelligence, KT Corp, Telefonica and Vodafone and outlines how the convergence of computing and communications will drive a step-change in productivity by delivering real-time services across multiple sectors such as entertainment, transportation and manufacturing. GSMA Intelligence estimates that there will be 1.4 billion global 5G connections by 2025 accounting for more than 15 per cent of the mobile market. “The combination of 5G, the IoT, Big Data and AI will impact almost every aspect of our daily lives from the way we consume entertainment to the way in which